ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. The stock should be watched closely. This upgrade primarily reflects an upward trend … In particular, AbbVie submitted the regulatory paperwork for three new indications for its arthritis therapeutic, Rinvoq, with the goal of offering the drug to a wider set of arthritis patients. What's Happening With AbbVie Inc Stock Today? Macroaxis provides AbbVie buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. Though there is no guarantee that the company will continue to increase its dividend over time, AbbVie's management has made it a priority so far. I think that AbbVie is worth buying if you're looking for a stalwart pharmaceutical company whose value will slowly appreciate thanks to its intelligently curated and growing sales base. Election Stock Watchlist: AbbVie, Amazon, Uber, Lyft. One of the regulatory submissions pertains to using the combination for mantle cell lymphoma (MCL) while the other aims to treat chronic lymphocytic leukemia (CLL). Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for AbbVie Inc stock to perform well in the short-term. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal The AbbVie Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. The company is also seeking two approvals for a pair of new therapies created from a combination of its oncology drugs, Imbruvica and Venclexta. AbbVie Inc (ABBV) stock is lower by -0.16% while the S&P 500 has gained 1.48% as of 3:01 PM on Thursday, Jul 2. The price target was set to $119.00 - $128.00. But there are two issues which should give potential investors pause. In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. Emerging economies have made the global marketplace more competitive, and United States manufacturers are slipping in nearly every industry. This is a drop from Humira's peak sales in 2018, when it brought in just over $19.9 billion over the entire year. If we double the $1.76 billion to estimate for a full quarter, AbbVie would be earning about $3.52 billion from Allergan. Of this $48 billion, the company expects that sales from its blockbuster biologic, Humira, will account for approximately 40%, which works out to be $19.2 billion, or around $4.8 billion per quarter. AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. AbbVie Inc finds support from accumulated volume at $104.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell. 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Over the last 30 days, this security got 1 buy, 0 sell and 0 hold ratings. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. This causes a divergence between volume and price and it may be an early warning. For the last week the stock has had a daily average volatility of 2.08%. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. He would favor ABBV, although it is a little riskier than JNJ. AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in several major territories. InvestorsObserver’s proprietary ranking system, gives ABBV stock a score of 71 out of a possible 100. First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. There are mixed signals in the stock today. Users should not base their investment decision upon "StockInvest.us". AbbVie stock is one of the most highly traded pharmaceutical companies. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. In other words, Allergan's revenues are only reflected for about half of the quarter. This number is deceptively low, however, as the Allergan deal closed on May 8 and the quarter ended on June 30. Second, there is the key question of how the company will replace flagging revenues from its best-selling drug Humira, which has faced increasing competition from biosimilar products since its patent protections expired in 2016. … Support: $104.58, AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Unless you're a diehard bargain hunter, now looks like a great time to buy. During the last day, the stock moved $2.39 between high and low, or 2.28%. In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. Although it might take a few years for these projects to eclipse Humira's present-day revenues, they should help ensure that the company's future is stable . AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the AbbVie Inc stock. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The AbbVie Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. In my view, the Allergan deal will be instrumental in addressing AbbVie's challenges with Humira. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Please read the full disclaimer here. Terms of Use and Privacy Policy. AbbVie is also attractive to investors thanks to its profitability, consistently growing revenues, and a meaty trailing dividend yield of 5.1%. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. All users should speak with their financial advisor before buying or selling any securities. The healthcare sector is a favorite for investors searching for dividend stocks to buy. How realistic is it for Allergan's sales to make up for Humira's decline? Buy Abbvie stock (ABBV). View IEX’s Terms of Use. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy Candidate candidate. (This stock has low daily movements and this gives low risk. The AbbVie Inc stock price gained 1.03% on the last trading day (Tuesday, 5th Jan 2021), rising from $105.41 to $106.50. Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising programs in oncology, immunology, neuroscience, and more. liable for your own investment decisions and agree to ABBV updated stock price target summary. View analyst ratings for AbbVie or view MarketBeat's top 5 stock picks. Resistance: $107.28 On corrections down, there will be some support from the lines at $105.11 and $103.98. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. However, there is one area where the US maintains worldwide leadership: pharmaceutical research and development. ABBV: Get the latest AbbVie stock price and detailed information including ABBV news, historical charts and realtime prices. It announced a definitive agreement to buy Allergan on … Stock Advisor launched in February of 2002. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.